AEZS - Aeterna Zentaris Inc.
| Previous Close | 3.1700 |
| Open | 3.1900 |
| Bid | 0.0000 x 800 |
| Ask | 3.2900 x 800 |
| Day's Range | 3.1177 - 3.2215 |
| 52 Week Range | 1.2900 - 5.5700 |
| Volume | 66,286 |
| Avg. Volume | 254,080 |
| Market Cap | 52.397M |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9240 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- GlobeNewswire•12 days ago
Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
CHARLESTON, S.C., May 08, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the.
- Zacks•13 days ago
Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
Aeterna Zentaris: 1Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and research and development costs, came to 14 cents per share. The drug ...
- GlobeNewswire•13 days ago
Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results
CHARLESTON, S.C., May 07, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the first quarter ended March 31,.
- Zacks•19 days ago
What's in the Cards for AEterna (AEZS) This Earnings Season?
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
- Zacks•22 days ago
Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Associated Press•2 months ago
Aeterna Zentaris: 4Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 31 cents per share. The drug developer posted revenue of $1.4 million in the period. For the year, the company reported net income of ...
- GlobeNewswire•2 months ago
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
Aeterna Zentaris Inc. (AEZS) (AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. The increase in total revenue in 2018 relates to license fees, royalty income and product sales associated with executing the License and Assignment Agreement for Macrilen™ (macimorelin) in January 2018.
- GlobeNewswire•2 months ago
Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
Aeterna Zentaris Inc. (AEZS) (AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.
- Zacks•2 months ago
Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Benzinga•2 months ago
The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
- GlobeNewswire•2 months ago
Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor
Aeterna Zentaris Inc. (AEZS) (AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Aeterna Zentaris. The Special Committee has approved the engagement by the Company of Torreya, a global investment bank specializing in life sciences, as its financial advisor. Torreya is working with management to assist the Special Committee and the board of directors in considering a wide range of transactions (including opportunities for the license of macimorelin outside of the United States and Canada, other monetization transactions relating to macimorelin or the potential sale of the company) which may create value for the company, its shareholders and other stakeholders.
- Zacks•3 months ago
What's in the Cards for Aeterna (AEZS) This Earnings Season?
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
- Zacks•3 months ago
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
- Zacks•3 months ago
4 Drug Stocks to Buy Despite Price Hearing Woes
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
- Zacks•3 months ago
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
- Zacks•3 months ago
5 Tiny Biotech Stocks With Superb Growth Potential
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
- Zacks•4 months ago
Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?
Is (AEZS) Outperforming Other Medical Stocks This Year?
- Zacks•4 months ago
Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.
- GlobeNewswire•4 months ago
Aeterna Zentaris Receives European Marketing Clearance for Macimorelin
Aeterna Zentaris Inc. (AEZS) (AEZS) announced that the European Medicines Agency (EMA) has granted marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). “Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition,” said Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin. AGHD may occur in an adult subject who has a history of childhood onset growth hormone deficiency (GHD) or may occur during adulthood as an acquired condition.
- Zacks•4 months ago
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
- Zacks•5 months ago
Aeterna Zentaris (AEZS) Stock Moves -1.16%: What You Should Know
In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.56, marking a -1.16% move from the previous day.
- GlobeNewswire•5 months ago
Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore
CHARLESTON, S.C., Dec. 21, 2018 -- Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS) has settled its previously disclosed litigation in South Carolina and Canada with former.
- Zacks•5 months ago
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Is (AEZS) Outperforming Other Medical Stocks This Year?
